Your session is about to expire
← Back to Search
MM-120 for Anxiety Disorders
Study Summary
This trial will test if MM-120 can effectively treat symptoms of generalized anxiety disorder. The trial will have 4 groups who will each receive a different dose of MM-120.
- Generalized Anxiety Disorder
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- You have an acceptable overall medical condition to be safely enrolled into and to complete the study.You can swallow pills.You are able to swallow pills.You or a close family member (parent or sibling) have been diagnosed with schizophrenia, posttraumatic stress disorder (PTSD), bipolar disorder or other serious mental health conditions.You have been diagnosed with a specific type of anxiety disorder called DSM-5 generalized anxiety disorder.You have been diagnosed with a specific type of anxiety disorder called DSM-5 generalized anxiety disorder.You are able to provide informed consent.
- Group 1: Arm 1- Placebo
- Group 2: Arm 4- 100 μg MM-120 (LSD D-Tartrate)
- Group 3: Arm 2- 25 μg MM-120 (LSD D-Tartrate)
- Group 4: Arm 5- 200 μg MM-120 (LSD D-Tartrate)
- Group 5: Arm 3- 50 μg MM-120 (LSD D-Tartrate)
- Screening: It may take up to 1 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 1 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Weeks after you stop receiving the treatment.
Frequently Asked Questions
Are recruitment efforts still active for this trial?
"Affirmative. According to information posted on clinicaltrials.gov, this trial is currently seeking participants since its inception on August 27th 2022 and as recently as November 17th 2022. The research requires 200 patients across 15 different sites for completion."
Has the Federal Drug Administration authorized MM-120 as a safe and effective treatment?
"MM-120's safety rating was assessed at 2, as it is currently in its second phase of clinical trials with limited data supporting efficacy."
How many sites are hosting this clinical investigation?
"This clinical trial is welcoming patients to participate at BioBehavioral Research of Austin in Austin, Texas; Hassman Research Institute in Berlin, New jersey; Irvine Center for Clinical Research in Irvine, California; and an additional 15 medical centres."
How many individuals have been admitted to the research project?
"To successfully complete this clinical trial, 200 qualified patients are needed. To find a location near them, participants can turn to BioBehavioral Research of Austin in Texas or Hassman Research Institute in New jersey."
Is there an opportunity to participate in this exploration?
"This clinical trial requires 200 participants who suffer from DSM-5 Generalized Anxiety Disorder, are between 18 and 74 years old, have a bodyweight of 50kg or more and an acceptable Body Mass Index (BMI) ranging from 18 to 38 mg/kg2. Additionally, they must be able to swallow capsules, provide informed consent and possess sound medical health in order to safely join the study."
Does the upper age limit for this medical trial extend beyond thirty years of age?
"This medical trial has an age criterion that requires all participants to be at least 18 years old and no older than 74."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Average response time
- < 2 Days
Most responsive sites:
- Segal Trials: < 24 hours
- BioBehavioral Research of Austin: < 24 hours
- Lutheran Hospital - Cleveland Clinic: < 48 hours
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger